8-K: Cyclacel Amends Merger Agreement with Fitters, Adds $1 Million Cash Payment and Extends Deadline

Cyclacel Pharmaceuticals, Inc. has amended its share exchange agreement with FITTERS Diversified Berhad, adding a $1 million cash payment to Fitters Parent due to a decline in Cyclacel's valuation and extending the closing deadline to September 30, 2025.

Summary

• Cyclacel Pharmaceuticals, Inc. (Cyclacel) entered into Amendment No. 1 to its Exchange Agreement with FITTERS Diversified Berhad (Fitters Parent) and FITTERS Sdn. Bhd. (Fitters Sub) on July 7, 2025.
• The original agreement, dated May 6, 2025, intended a voluntary share exchange where Fitters Parent would exchange 100% of Fitters Sub's capital shares for 19.99% of Cyclacel's common stock.
• The amendment introduces an additional consideration: Cyclacel will pay USD $1,000,000, or a mutually agreed upon amount, to Fitters Parent at closing.
• This cash payment was added because the parties agreed that Cyclacel's valuation had declined since the initial agreement.
• The amendment also extends the "Final Date" for the transaction to September 30, 2025.
• The transaction remains subject to approval from Cyclacel stockholders and FITTERS.
• The Boards of Directors of Cyclacel, FITTERS, and Fitters Sub have unanimously approved the Exchange Agreement.
• For U.S. federal income tax purposes, the exchange is considered a taxable disposition of shares by Fitters Parent and an acquisition by Cyclacel.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the transaction is proceeding, the need for an additional cash payment due to a 'declined valuation' of Cyclacel and the extension of the closing deadline are negative indicators. The diversification strategy itself could be positive long-term, but the immediate news points to challenges.

Positives

• The Boards of Directors of Cyclacel, FITTERS, and Fitters Sub have unanimously approved the Exchange Agreement, indicating strong internal alignment.
• The amendment allows the transaction to proceed despite a decline in Cyclacel's valuation, suggesting commitment from all parties to complete the strategic acquisition.
• The acquisition of Fitters Sdn. Bhd. will diversify Cyclacel's business into fire safety materials, equipment, and prevention systems, potentially broadening its revenue streams beyond biopharmaceuticals.

Negatives

• Cyclacel's valuation has declined since the original agreement, necessitating an additional cash payment of USD $1,000,000 to Fitters Parent.
• The closing date for the transaction has been extended from an implied earlier date to September 30, 2025, indicating a delay in the consummation of the deal.

Risks

• Conditions to the closing of the proposed transaction may not be satisfied, including failure to obtain timely stockholder approval or required regulatory clearances.
• Uncertainties exist regarding the timing of the consummation of the proposed transaction and the ability of each party to complete it.
• Cyclacel and Fitters Sub may be unable to successfully integrate their businesses or achieve anticipated synergies.
• Other anticipated benefits of the proposed transaction, such as revenues, expenses, earnings, financial results, growth, expansion, and tax treatment, may not be realized.
• Potential litigation related to the proposed transaction could be instituted against Cyclacel, Fitters Sub, FITTERS Parent, or their respective directors.
• Possible disruptions from the proposed transaction could harm the respective businesses of Cyclacel and Fitters Sub.
• The ability of Cyclacel and Fitters Sub to retain, attract, and hire key personnel may be impacted.
• Potential adverse reactions or changes to relationships with customers, employees, suppliers, or other parties may result from the announcement or completion of the proposed transaction.
• Business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction could affect Cyclacel's or Fitters Sub's financial performance.
• Certain restrictions during the pendency of the proposed transaction may impact Cyclacel's or Fitters Sub's ability to pursue certain business opportunities or strategic transactions.
• Legislative, regulatory, and economic developments could affect the transaction.
• Unpredictability and severity of catastrophic events, including acts of terrorism or outbreak of war or hostilities, could impact the transaction.
• Other factors detailed in Cyclacel's Form 10-K for the fiscal year ended December 31, 2024, could also affect actual results.

Future Outlook

The transaction is expected to close by September 30, 2025, subject to stockholder and regulatory approvals. The combined entity aims to integrate businesses successfully and achieve anticipated synergies, though there are explicit risks that these benefits may not be realized.

Management Comments

• The Boards of Directors of Parent [Cyclacel], Fitters Parent and the Company [Fitters Sub] have (a) determined that this Agreement, the Exchange and the transactions contemplated under this Agreement is in the best interest of each company and its respective shareholders, (b) approved the Exchange, (c) adopted this Agreement and (d) determined to recommend that its shareholders adopt, authorize and approve this Agreement, the Exchange and the transactions contemplated under this Agreement.

Industry Context

This announcement signifies Cyclacel's strategic move to diversify its business beyond its core biopharmaceutical focus into the fire safety and protective materials sector through the acquisition of Fitters Sdn. Bhd. This could be a strategy to broaden revenue streams and reduce reliance on the high-risk, long-development-cycle biopharmaceutical industry, potentially providing more stable cash flows.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the transaction in the context of global benchmarks. Therefore, a detailed comparison is not possible based solely on the provided information.

Corporate Governance

Legal Proceedings

• Potential litigation relating to the proposed transaction could be instituted against Cyclacel, Fitters Sub, FITTERS Parent, or their respective directors.

Stakeholder Impact

• Shareholders (Cyclacel): Will experience dilution from the issuance of 19.99% of common stock and the company will incur a $1,000,000 cash outflow. The valuation decline leading to the cash payment is a negative. The strategic diversification could be a long-term benefit, but the immediate news is concerning.
• Shareholders (Fitters Parent): Will receive 19.99% of Cyclacel's common stock plus a $1,000,000 cash payment, which is an improved consideration compared to the original agreement.
• Employees (Cyclacel & Fitters Sub): May face business uncertainty and potential disruptions during the pendency of the transaction. The ability to retain, attract, and hire key personnel is a risk.
• Customers & Suppliers (Cyclacel & Fitters Sub): Potential adverse reactions or changes to relationships could occur due to the announcement or completion of the transaction.

Next Steps

• Cyclacel intends to file a registration statement on Form S-4 with the SEC, which will include a proxy statement/prospectus for the proposed transaction.
• The transaction requires approval from Cyclacel stockholders and FITTERS.
• The closing of the Exchange is expected to occur no later than three business days after conditions are satisfied or waived, with a new Final Date of September 30, 2025.
• If applicable, Cyclacel may make an election under Section 338(g) of the Code with respect to its acquisition of the shares.

Key Dates

Recommendation

Keywords

Cyclacel Pharmaceuticals, FITTERS Diversified Berhad, FITTERS Sdn. Bhd., share exchange, merger agreement, acquisition, biopharmaceutical, fire safety, corporate diversification, SEC filing, Form 8-K, M&A, NASDAQ, CYCC, CYCCP, Malaysia